Table 1.

Clinicopathologic characteristics of the patients included in the efficacy analysis

No. of patients (anti-EGFR + bev)No. of patients (anti-EGFR)No. of patients (bev)
VariableN = 580 (100%)N = 255 (44%)N = 325 (56%)
Age (years)
  Median (range)65 (21–88)65 (32–88)65 (21–86)
Gender
  Male/female382 (65.86)/192 (33.1)185 (72.55)/70 (27.45)197 (60.61)/122 (37.54)
  Unknown6 (1.03)0 (0)6 (1.85)
Tumor location
  Right colon169 (29.14)53 (20.78)116 (35.69)
  Left colon55 (9.48)25 (9.8)30 (9.23)
  Rectum217 (37.41)93 (36.47)124 (38.15)
  Colon unspecified132 (22.76)81 (31.76)51 (15.69)
  Unknown7 (1.2)3 (1.17)4 (1.23)
TNM stage
  I–II5 (0.86)/45 (7.76)3 (1.18)/18 (7.06)2 (0.62)/27 (8.3)
  III–IV136 (23.45)/381 (65.69)66 (25.88)/161 (63.13)70 (21.53)/220 (67.7)
  Unknown13 (2.24)7 (2.74)6 (1.85)
Primary tumor resection
  Yes/No459 (79.14)/54 (9.31)172 (67.45)/18 (7.05)287 (88.3)/36 (11.07)
  Unknown67 (11.55)65 (25.5)2 (0.62)
Metastasis resection
  Yes/no168 (28.97)/342 (58.97)66 (25.88)/123 (48.24)102 (31.38)/219 (67.38)
  Unknown70 (12.06)66 (25.88)4 (1.23)
Treatment intention
  First-line355 (61.21)84 (32.94)271 (83.38)
  Second-line95 (16.38)68 (26.67)27 (8.31)
  Neoadjuvant34 (5.86)28 (10.98)6 (1.85)
  Other96 (16.55)75 (29.41)21 (6.46)
Biological treatment
  Cetuximab120 (20.69)120 (47.06)
  Panitumumab135 (23.28)135 (52.94)
  Bevacizumab325 (56.03)325 (100)
Chemotherapy regimens—clinical trials
  NCT01071655 (SETICC)70 (12.07)70 (21.54)
  NCT00958386 (SPECTRA)33 (5.69)33 (12.94)
  NCT00885885 (PLANET)42 (7.24)42 (16.47)
  NCT01126112 (FRAIL)15 (2.59)15 (5.88)
  NCT01704703 (ULTRA)32 (5.52)32 (12.55)
Chemotherapy regimens—no clinical trials
 FU based chemotherapy + bevacizumab
  1st line/2nd line201 (34.66)/27 (4.66)201 (61.85)/27 (8.31)
  3rd line and beyond12 (2.07)12 (3.69)
  Other15 (2.59)15 (4.61)
 FU based chemotherapy + cetuximab
  1st line/2nd line36 (6.21)/7 (1.21)36 (14.12)/7 (2.74)
  3rd line and beyond2 (0.34)2 (0.78)
  Other8 (1.38)8 (3.14)
 FU based chemotherapy + panitumumab
  1st line/2nd line7 (1.21)/1 (0.17)7 (2.74)/1 (0.4)
 Irinotecan + anti-EGFR
  1st line/2nd line7 (1.21)/23 (3.96)7 (2.74)/23 (9.02)
  3rd line and beyond22 (3.79)22 (8.63)
  Other2 (0.34)2 (0.78)
 Anti-EGFR monotherapy18 (3.1)18 (7.06)
Tumor response
  Complete response/partial response27 (4.66)/180 (31.03)10 (3.92)/80 (31.37)17 (5.23)/100 (30.77)
  Stable disease/progressive disease216 (37.24)/88 (15.17)87 (34.12)/46 (18.04)129 (39.7)/42 (12.92)
  Not evaluable69 (11.9)32 (12.55)37 (11.38)